Review
Oncology
Janah Vandenhoeck, Jan P. van Meerbeeck, Erik Fransen, Jo Raskin, Guy Van Camp, Ken Op de Beeck, Kevin Lamote
Summary: This study provides a systematic review of the research investigating DNA methylation in mesothelioma, identifying APC, miR-34b/c, and WIF1 as the most suitable candidate biomarkers. Further research on genome-wide DNA methylation profiling is needed for potential clinical applications.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Selina Tsim, Laura Alexander, Caroline Kelly, Ann Shaw, Samantha Hinsley, Stephen Clark, Matthew Evison, Jayne Holme, Euan J. Cameron, Davand Sharma, Angela Wright, Seamus Grundy, Douglas Grieve, Alina Ionescu, David P. Breen, Elankumaran Paramasivam, Ioannis Psallidas, Dipak Mukherjee, Mahendran Chetty, Giles Cox, Alan Hart-Thomas, Rehan Naseer, John Edwards, Cyrus Daneshvar, Rakesh Panchal, Mohammed Munavvar, Rachel Ostroff, Leigh Alexander, Holly Hall, Matthew Neilson, Crispin Miller, Carol McCormick, Fiona Thomson, Anthony J. Chalmers, Nick A. Maskell, Kevin G. Blyth
Summary: The study confirms that SOMAscan proteomics may be useful as a future screening test for MPM in asbestos-exposed individuals. However, both fibulin-3 and SOMAscan are not suitable for diagnosis or pathway stratification.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Medicine, General & Internal
Cita Zupanc, Alenka Franko, Danijela Strbac, Metoda Dodic Fikfak, Viljem Kovac, Vita Dolzan, Katja Goricar
Summary: The study evaluated serum calretinin as a potential biomarker in asbestos-related diseases, particularly in predicting malignant mesothelioma with high accuracy. Combining calretinin and SMRP showed the highest predictive value in distinguishing MM from other asbestos-related diseases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Lorenzo Zallocco, Roberto Silvestri, Federica Ciregia, Alessandra Bonotti, Riccardo Marino, Rudy Foddis, Antonio Lucacchini, Laura Giusti, Maria Rosa Mazzoni
Summary: This study found that the levels of prosaposin and SULF-1 in pleural effusion may be promising biomarkers for differentiating between mesothelioma and non-malignant pleural disease. However, more patients need to be enrolled to confirm the usefulness of these soluble proteins in differentiating mesothelioma pleural effusions from those linked to lung cancer.
Article
Medicine, General & Internal
Amal F. Gharib, Muhammad Alaa Eldeen, Amany Salah Khalifa, Wael H. Elsawy, Emad Mohamed Eed, Ahmad El Askary, Refaat A. Eid, Mohamed A. Soltan, Nermin Raafat
Summary: Malignant pleural mesothelioma is a malignant tumor related to asbestos exposure, and GPX1 gene expression level may play a role in the pathogenicity of cancer, with higher levels associated with shorter survival time in patients.
Article
Biochemical Research Methods
Ping Lin, Yuean Zhao, Xiaoqian Li, Zongan Liang
Summary: This study identified several hub genes relevant to Malignant Pleural Mesothelioma (MPM), including NUSAP1, PLOD2, and KIAA0101. Among these genes, KIAA0101 appears to be a useful diagnostic and prognostic biomarker for MPM, which may provide new clues for MPM diagnosis and therapy.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
(2022)
Article
Oncology
Zhenying Guo, Li Shen, Ningning Li, Xiaoxiao Wu, Canming Wang, Zheng Gu, Zhongjian Chen, Junping Liu, Weimin Mao, Yuchen Han
Summary: This study used bioinformatics to identify key genes in malignant mesothelioma, finding that Aurora-A could be an optimal diagnostic biomarker and a potential prognostic marker. Additionally, seven genes were identified as potential prognostic markers for MM.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Melanie Vogl, Anna Rosenmayr, Tomas Bohanes, Axel Scheed, Milos Brndiar, Elisabeth Stubenberger, Bahil Ghanim
Summary: Malignant pleural mesothelioma (MPM) is an aggressive disease with limited treatment options and poor prognosis, with asbestos exposure and chronic inflammation as main risk factors. The suppression of the specific immune system and activation of the innate immune system are crucial drivers of MPM aggressiveness, leading to unfavorable patient outcomes. Identifying new biomarkers can help personalize patient therapy, avoid ineffective treatments, and ultimately improve outcomes in this rare disease.
Article
Medicine, Research & Experimental
Vilde Drageset Haakensen, Anna K. Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanaes, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M. Cedres, Aslaug Helland
Summary: The NIPU study is a phase II clinical trial aiming to compare the efficacy and safety of nivolumab and ipilimumab with or without telomerase vaccine in patients with inoperable malignant pleural mesothelioma after first-line platinum-based chemotherapy. The study seeks to improve treatment response by combining checkpoint inhibition with a telomerase vaccine and also to explore mechanisms for treatment response and resistance.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Review
Oncology
Jing-Jing Wang, Li Yan
Summary: Currently, there are several available serum biomarkers for diagnosing MPM, but their diagnostic accuracy is unsatisfactory with sensitivity and specificity both less than 0.90. Many previous studies have limitations, particularly in the representativeness of the study cohort. Further research is needed to explore novel serum biomarkers for MPM diagnosis.
TRANSLATIONAL CANCER RESEARCH
(2022)
Review
Oncology
Alex Dipper, Nick Maskell, Anna Bibby
Summary: Malignant pleural mesothelioma (MPM) presents diagnostic challenges, with ancillary diagnostic tests such as immunocytochemical markers, molecular techniques, diagnostic biomarkers, and imaging discussed in cases where histological samples are unavailable or inconclusive. While no single adjunctive test has the sensitivity and specificity to diagnose MPM in isolation, correlation of pleural fluid cytology with radiology and biomarkers can help make an MDT-consensus diagnosis when invasive tests are not feasible.
Article
Medicine, General & Internal
Claire Y. Li, Timothy Kennedy, Henry Richard Alexander
Summary: Malignant peritoneal mesothelioma is a rare malignancy that is diagnosed through cross sectional imaging and tissue biopsy. Surgical cytoreduction and chemotherapy are the preferred treatments, providing prolonged benefits to many patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cell Biology
Jingwen Yang, Weiwei Dong, He Zhang, Huixia Zhao, Zhiyan Zeng, Fengyun Zhang, Qiuwen Li, Xiaohong Duan, Yanyan Hu, Wenhua Xiao
Summary: This study revealed that the exosomal microRNA panel has high accuracy in diagnosing HCC and has important clinical significance.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Multidisciplinary Sciences
Masayuki Watanabe, Tomohito Higashi, Kana Ozeki, Atsuko Y. Higashi, Kotaro Sugimoto, Hayato Mine, Hironori Takagi, Yuki Ozaki, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki, Hideki Chiba
Summary: This study identified claudin-15 as a potential positive marker for malignant pleural mesotheliomas, with high expression levels in 83% of MPM tissue samples. The specificity of CLDN15 was comparable to other markers in lung adenocarcinoma sections. CLDN15 showed low expression in non-mesothelial tumors, suggesting its potential clinical utility for MPM diagnosis.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Beatrice Dozin, Grazia Carbotti, Silvio Roncella, Paola Ferro, Paolo Dessanti, Pier Aldo Canessa, Silvano Ferrini, Marina Fabbi
Summary: This study suggests that a high level of IFN-gamma in pleural effusion may be associated with better survival in malignant pleural mesothelioma patients and could potentially serve as a prognostic biomarker. Larger prospective studies are needed to confirm these findings.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)